Arjuna Terminalia arjuna (Roxb. ex DC.) Wight & Arn.
Also called: Terminalia arjuna, Arjun, Pentaptera arjuna Roxb. ex DC. (synonym)
Arjuna is a tree of seasonally dry tropical South Asia whose stem bark has been used for centuries in Ayurveda as a cardiotonic. Studied preparations are bark powder and bark extracts, including water extracts, taken by mouth.
- Category
- Botanical
- Part used
- Stem bark (powder or extract)
- Strongest evidence
- C Limited
- Native range
- Native to the Indian Subcontinent and Myanmar (POWO lists Assam, Bangladesh, India, Myanmar, Pakistan and Sri Lanka); introduced in southeast China, Mauritius, Rodrigues, Trinidad-Tobago, Venezuela and the Venezuelan Antilles
- Reviewed
- 2026-10-30
Class 1 Well studied in people. No review stating a count of single-ingredient trials was found. This entry cites 10 RCTs of arjuna alone: sources 3-12, bark powder or extract versus placebo or a drug control, 2001-2026, 18 to 116 participants. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels7 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Heart failure (as add-on to standard therapy) | C | A 2026 meta-analysis of nine studies (537 patients) found lower left ventricular mass and higher HDL cholesterol, but no significant change in ejection fraction, blood pressure, triglycerides or LDL. [1] |
| Chronic heart failure: ejection fraction | X | In a 12-week double-blind RCT of 100 patients on standard therapy, 750 mg twice daily of a bark water extract did not change ejection fraction or most secondary outcomes versus placebo. [3] |
| Chronic stable angina | C | A 2014 systematic review found studies of poor methodological design and no significant difference from control in pooled outcomes; it judged the evidence insufficient for any conclusion. [2] |
| Cholesterol in coronary heart disease | C | In a 30-day randomized trial of 105 patients, 500 mg/day bark powder lowered total cholesterol (-9.7%) and LDL (-15.8%) within the group; placebo and vitamin E groups showed no lipid changes. [4] |
| Blood pressure in stage 1 hypertension | C | In a 28-day triple-blind RCT of 44 patients on telmisartan, 3 g/day arjuna lowered systolic and diastolic blood pressure more than placebo. [12] |
| Heart pumping measures in healthy adults | C | In an 8-week RCT of 72 healthy adults aged 30-70, 400 mg/day of a proprietary aqueous bark extract raised ejection fraction 6.28% from baseline versus 0.24% with placebo; one author reported a company affiliation and personal fees. [11] |
| Heart measures in young men who exercise | C | In a 56-day RCT of 32 healthy male endurance exercisers, 400 mg/day of the same proprietary bark extract improved left ventricular ejection fraction versus placebo. [9] |
Main constituents: Bark extract described as containing acids (arjunic acid, terminic acid), glycosides (arjunetin, arjunosides I-IV), flavones, tannins and oligomeric proanthocyanidins, plus minerals [5]; Saponins and flavonoids [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 500 mg bark extract every 8 hours for one week (crossover angina trial). [5]
- 750 mg bark water extract twice daily for 12 weeks (chronic heart failure trial). [3]
- 400 mg/day standardized aqueous bark extract for 8 weeks (healthy adults). [11]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- A 2014 systematic review found 15 adverse events in 2 studies (78 patients): constipation (4), headache (3), body ache (3), abdominal discomfort (2), and one each of dizziness, pedal edema and transient cardiac failure. [2]
- The bark water extract was well tolerated in a 12-week RCT of 100 heart-failure patients. [3]
- No significant untoward effects were reported during arjuna therapy in a crossover angina trial of 58 men. [5]
Identity, quality and standardization
- A 2014 systematic review noted poor randomization, allocation concealment and blinding, and a maximum sample size of 58 in angina studies. [2]
Regulatory status
- US: by law, FDA does not approve dietary supplements or their labeling before they are marketed. [13]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Arjunic acid, terminic acid, arjunetin and arjunosides I-IV, with flavones, tannins and oligomeric proanthocyanidins (constituents of bark extract) Acids and glycosides (as the source groups them); flavones; tannins; proanthocyanidins [P1]
- Saponins and flavonoids (bioactive compounds reported in the bark) Saponins; flavonoids [P2]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming arjuna (Terminalia arjuna) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P4]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P7]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Bharani A, et al. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J 2002;54(2):170-5 (PMID 12086380), 2002-03. pubmed.ncbi.nlm.nih.gov
- Kaur N, et al. Terminalia arjuna in chronic stable angina: systematic review and meta-analysis. Cardiol Res Pract 2014;2014:281483 (PMID 24600529), 2014. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1-142 (last updated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list, TR-001 to TR-606 (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- GBIF species API: IUCN Red List category for Terminalia arjuna (Roxb. ex DC.) Wight & Arn., 2026-10-29. api.gbif.org
Sources
- Kumar A, Ul Haque Z, Rai A. Evaluation of the therapeutic potential and safety of Terminalia arjuna in heart failure management: a systematic review and meta-analysis of randomized controlled trials. Ann Afr Med 2026 (online ahead of print) (PMID 42389976), 2026-07-01. pubmed.ncbi.nlm.nih.gov
- Kaur N, et al. Terminalia arjuna in chronic stable angina: systematic review and meta-analysis. Cardiol Res Pract 2014;2014:281483 (PMID 24600529), 2014. pubmed.ncbi.nlm.nih.gov
- Maulik SK, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial. Phytomedicine 2016;23(11):1211-9 (PMID 26988798), 2016-10-15. pubmed.ncbi.nlm.nih.gov
- Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. J Assoc Physicians India 2001;49:231-5 (PMID 11225136), 2001-02. pubmed.ncbi.nlm.nih.gov
- Bharani A, et al. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J 2002;54(2):170-5 (PMID 12086380), 2002-03. pubmed.ncbi.nlm.nih.gov
- Bharani A, Ahirwar LK, Jain N. Terminalia arjuna reverses impaired endothelial function in chronic smokers. Indian Heart J 2004;56(2):123-8 (PMID 15377133), 2004-03. pubmed.ncbi.nlm.nih.gov
- Dwivedi S, Aggarwal A, Agarwal MP, Rajpal S. Role of Terminalia arjuna in ischaemic mitral regurgitation. Int J Cardiol 2005;100(3):507-8 (PMID 15837100), 2005-04-28. pubmed.ncbi.nlm.nih.gov
- Kapoor D, et al. Short-term adjuvant therapy with Terminalia arjuna attenuates ongoing inflammation and immune imbalance in patients with stable coronary artery disease: in vitro and in vivo evidence. J Cardiovasc Transl Res 2015;8(3):173-86 (PMID 25827448), 2015-04. pubmed.ncbi.nlm.nih.gov
- Girandola RN, Srivastava S. Effect of E-OJ-01 on cardiac conditioning in young exercising adults: a randomized controlled trial. Am J Ther 2017;24(3):e298-e307 (PMID 27930383), 2017-05. pubmed.ncbi.nlm.nih.gov
- Saleem S, Ansari AH, Ansari A. Effect of Arjun Chāl on cardiovascular risk factors: a randomized controlled clinical trial. J Complement Integr Med 2021;19(1):145-154 (PMID 33977687), 2021-05-10. pubmed.ncbi.nlm.nih.gov
- Srivastava S, Girandola RN, Abedon B. Effect of E-OJ-01 on left ventricular ejection fraction and myocardial oxygen consumption: a randomized, double-blind, placebo-controlled study. J Multidiscip Healthc 2022;15:2511-2525 (PMID 36349244), 2022-11-02. pubmed.ncbi.nlm.nih.gov
- Nazir A, Bhat MDA, Mir UY. Efficacy of Terminalia arjuna in essential hypertension: a randomized controlled study. Explore (NY) 2026;22(6):103535 (PMID 42753288), 2026-09-12. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Terminalia arjuna (Roxb. ex DC.) Wight & Arn. (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arnica · Aronia (black chokeberry) · Asafoetida · Ashwagandha · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.